All In Biotech

Drug Trial Radar · NCT05891158

A Study About Fazirsiran in People With and Without Liver Problems

An Open-Label, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics in Response to a Single Subcutaneous Dose of Fazirsiran (TAK-999) in Subjects With or Without Hepatic Impairment

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

34

Actual

Start

Oct 5, 2023

Primary completion

Sep 3, 2025

Study completion Sep 3, 2025

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Jun 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main aim of this study is to learn how the body processes fazirsiran (pharmacokinetics \[PK\]) in people with mild, moderate, or severe liver problems, compared to people with normal liver function. The study will include participants with liver scarring (cirrhosis) and mild, moderate, or severe liver problems, and participants with normal liver function. All participants will be given 1 injection of fazirsiran and will be followed up for 6 months after the fazirsiran injection.

Conditions

  • Hepatic Impairment

Interventions

  • FazirsiranDrug

    Fazirsiran SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of FazirsiranTime frame: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 9, 24, 48, 360, 1368, 2160 and 4320 hours post-dose
  2. Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of FazirsiranTime frame: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 9, 24, 48, 360, 1368, 2160 and 4320 hours post-dose
  3. Maximum Observed Plasma Concentration (Cmax) of FazirsiranTime frame: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 9, 24, 48, 360, 1368, 2160 and 4320 hours post-dose

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • CRU Hungary Kft

    Kistarcsa, Hungary

  • Summit Clinical Research s.r.o.

    Bratislava, Slovakia

  • Summit Clinical Research s.r.o.

    Malacky, Slovakia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.